Summary of Study ST003974
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002490. The data can be accessed directly via it's Project DOI: 10.21228/M8SC2K This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003974 |
| Study Title | Metabolomic profiles of albendazole treated T. spiralis adult worms |
| Study Summary | Trichinella spiralis is the parasitic nematodes that cause trichinellosis. Patients are infected with T. spiralis by consuming raw meat containing larval stage of the parasite. Patients may develop weakness, muscle pain, facial edema, or death in severe cases. Albendazole (ABZ) is the drug of choice for trichinellosis, however, the resistance to ABZ has been repeatedly reported. Hence, novel drugs against this parasite are essentially required. Developing new drugs is expensive and time-consuming. To overcome these limitations, the application of computational approaches and drug repurposing strategy would be a suitable solution. Here, we aimed to discover new anthelmintic drugs for T. spiralis using in silico-based techniques and in vitro validation. Firstly, we treated both adult and larval stages of T. spiralis with ABZ, then metabolome of the parasites were extracted. Following liquid chromatography-tandem mass spectrometry analysis, an approximately of 11,187-11,191 features were identified from XCMS online platform. From the metabolome data, there were 122 and 133 metabolites those were significantly changed by ABZ treatment in adult and larval stages, respectively. The pathway analysis was performed with Metaboanalyst platform and fatty acid degradation pathway was highlighted in both stages of the parasites. This pathway is vital for lipid metabolism of the worms, hence, we screened for potential drug targets in this pathway. We found that Carnitine palmitoyl transferase (CPT) 1 and 2 are the enzymes responsible for transporting fatty acids into mitochondria. Inhibiting these enzymes would shut down the lipid metabolism machinery of the parasites. Hence, these enzymes were proposed as the potential drug targets for trichinellosis treatment in the future. |
| Institute | Chulabhorn Royal Academy |
| Department | Princess Srisavangavadhana Faculty of Medicine |
| Last Name | Chienwichai |
| First Name | Peerut |
| Address | 906, Kamphaeng Phet 6 Rd., Lak Si, Bangkok, 10210, Thailand |
| peerut.chi@cra.ac.th | |
| Phone | +6681687460 |
| Submit Date | 2025-06-06 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML, wiff |
| Analysis Type Detail | LC-MS |
| Release Date | 2025-08-26 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002490 |
| Project DOI: | doi: 10.21228/M8SC2K |
| Project Title: | Metabolomic profiles of albendazole treated T. spiralis worms |
| Project Summary: | Trichinella spiralis is the parasitic nematodes that cause trichinellosis. Patients are infected with T. spiralis by consuming raw meat containing larval stage of the parasite. Patients may develop weakness, muscle pain, facial edema, or death in severe cases. Albendazole (ABZ) is the drug of choice for trichinellosis, however, the resistance to ABZ has been repeatedly reported. Hence, novel drugs against this parasite are essentially required. Developing new drugs is expensive and time-consuming. To overcome these limitations, the application of computational approaches and drug repurposing strategy would be a suitable solution. Here, we aimed to discover new anthelmintic drugs for T. spiralis using in silico-based techniques and in vitro validation. Firstly, we treated both adult and larval stages of T. spiralis with ABZ, then metabolome of the parasites were extracted. Following liquid chromatography-tandem mass spectrometry analysis, an approximately of 11,187-11,191 features were identified from XCMS online platform. From the metabolome data, there were 122 and 133 metabolites those were significantly changed by ABZ treatment in adult and larval stages, respectively. The pathway analysis was performed with Metaboanalyst platform and fatty acid degradation pathway was highlighted in both stages of the parasites. This pathway is vital for lipid metabolism of the worms, hence, we screened for potential drug targets in this pathway. We found that Carnitine palmitoyl transferase (CPT) 1 and 2 are the enzymes responsible for transporting fatty acids into mitochondria. Inhibiting these enzymes would shut down the lipid metabolism machinery of the parasites. Hence, these enzymes were proposed as the potential drug targets for trichinellosis treatment in the future. |
| Institute: | Chulabhorn Royal Academy |
| Department: | Princess Srisavangavadhana Faculty of Medicine |
| Last Name: | Chienwichai |
| First Name: | Peerut |
| Address: | 906, Kamphaeng Phet 6 Rd., Lak Si, Bangkok, 10210, Thailand |
| Email: | peerut.chi@cra.ac.th |
| Phone: | +66816874608 |
Subject:
| Subject ID: | SU004111 |
| Subject Type: | Invertebrate |
| Subject Species: | Trichinella spiralis |
| Taxonomy ID: | 6334 |
Factors:
Subject type: Invertebrate; Subject species: Trichinella spiralis (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample source | Stage | Treatment |
|---|---|---|---|---|
| SA454249 | 20220526_Trichinella adult 1000ng AB2_2 | Trichinella spiralis | Adult | ABZ treatment |
| SA454250 | 20220526_Trichinella adult 1000ng AB2_1 | Trichinella spiralis | Adult | ABZ treatment |
| SA454251 | 20220526_Trichinella adult 1000ng AB2_3 | Trichinella spiralis | Adult | ABZ treatment |
| SA454252 | 20220526_Trichinella adult 1000ng AB2_4 | Trichinella spiralis | Adult | ABZ treatment |
| SA454253 | 20220526_Trichinella adult 1000ng AB2_5 | Trichinella spiralis | Adult | ABZ treatment |
| SA454254 | 20220526_Trichinella adult 0.1% DMSO_1 | Trichinella spiralis | Adult | Control |
| SA454255 | 20220526_Trichinella adult 0.1% DMSO_2 | Trichinella spiralis | Adult | Control |
| SA454256 | 20220526_Trichinella adult 0.1% DMSO_3 | Trichinella spiralis | Adult | Control |
| SA454257 | 20220526_Trichinella adult 0.1% DMSO_4 | Trichinella spiralis | Adult | Control |
| SA454258 | 20220526_Trichinella adult 0.1% DMSO_5 | Trichinella spiralis | Adult | Control |
| Showing results 1 to 10 of 10 |
Collection:
| Collection ID: | CO004104 |
| Collection Summary: | Trichinella spiralis adult worms were treated with IC50 concentration of albendazole, then the worms were collected for metabolite extraction |
| Sample Type: | Worms |
Treatment:
| Treatment ID: | TR004120 |
| Treatment Summary: | Worms were treated with IC50 concentration of albendazole |
Sample Preparation:
| Sampleprep ID: | SP004117 |
| Sampleprep Summary: | All worms from each condition were transferred into 1.5-mL microcentrifuge tubes and homogenized in 500 μL methanol. At which point, the tubes were snap-frozen in liquid nitrogen and thawed prior to centrifuging at 800 × g for 1 min at 4°C. The supernatant was collected and placed in a new tube, and the pellet was extracted again with the same protocol. Following centrifugation, the supernatant from the second extraction was pooled into a tube containing the supernatant from the first extraction. The pellet was resuspended in 250 μL of deionized H2O before snap-freezing in liquid nitrogen and thawing. The supernatant was obtained by centrifugation at 15,000 × g for 1 min at 4°C and then pooled with the previous tube. The tubes containing the pooled supernatants were centrifuged at 15,000 × g for 1 min at 4°C to remove the remaining debris. The clear supernatant was transferred to a new tube and later dried in a speed vacuum. |
Chromatography:
| Chromatography ID: | CH004965 |
| Instrument Name: | Agilent 1260 |
| Column Name: | Waters Acquity BEH C8 (100 x 2.1 mm, 1.7 μm) |
| Column Temperature: | 40℃ |
| Flow Gradient: | 5% mobile phase B for 2.0 min (0.0–2.0 min), 5%–60% B for 0.5 min (2.0–2.5 min), 60%–80% B for 1.5 min (2.5–4.0 min), 80%–100% B for 8.0 min (4.0–12.0 min), 100% B for 5 min (12.0–17.0 min), 100%–5% B for 0.1 min (17.0–17.1 min), and 5% B for 2.9 min (17.1–20.0 min). |
| Flow Rate: | 0.3 mL/min |
| Solvent A: | 100% Water; 0.1% Formic acid |
| Solvent B: | 100% Acetonitrile; 0.1% Formic acid |
| Chromatography Type: | Reversed phase |
Analysis:
| Analysis ID: | AN006544 |
| Analysis Type: | MS |
| Chromatography ID: | CH004965 |
| Has Mz: | 1 |
| Has Rt: | 1 |
| Rt Units: | Minutes |
| Results File: | ST003974_AN006544_Results.txt |
| Units: | peak intensity |
| Analysis ID: | AN006545 |
| Analysis Type: | MS |
| Chromatography ID: | CH004965 |
| Has Mz: | 1 |
| Has Rt: | 1 |
| Rt Units: | Minutes |
| Results File: | ST003974_AN006545_Results.txt |
| Units: | peak intensity |